Enliven Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$119.7 | -$104.6 | -$83.5 | -$38.8 | -$51.4 |
| Net income | -$103.7 | -$89.0 | -$71.6 | -$37.7 | -$51.4 |
| Cash Flow Statement | |||||
| Free cash flow | -$70.5 | -$73.2 | -$61.4 | -$32.7 | -$46.8 |
Shares outstanding 73.3M · Free float 62.2%
Annual filing data through FY ended December 31, 2025; float as of October 3, 2026.